LENZ Therapeutics (LENZ) vs Zura Bio (ZURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Zura Bio (ZURA) has outperformed LENZ Therapeutics (LENZ) over the past year, losing 74.4% versus a loss of 90.0%. LENZ Therapeutics is the larger company by market cap ($93.2 million vs $89.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LENZ | ZURA |
|---|---|---|
| Share price | $2.97 | $0.9305 |
| Market cap | $93.16M | $89.63M |
| 1-day change | -11.23% | -2.30% |
| YTD return | -81.47% | -82.24% |
| 1-year return | -89.97% | -74.37% |
| 5-year return | -95.57% | — |
| EPS (TTM) | $-4.53 | $-1.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $19.09M | — |
| Net income (latest FY) | $-82.13M | $-68.65M |
| Gross margin | 97.81% | — |
| Operating margin | -477.46% | — |
| Net margin | -430.25% | — |
| 52-week high | $32.13 | $7.44 |
| 52-week low | $2.80 | $0.919 |
| Distance from 52-week high | -90.77% | -87.49% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +400.17% | +759.75% |
| Average volume | 892.30K | 4.47M |
| Shares outstanding | 31.42M | 96.33M |
| Employees | 40 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZURA has outperformed LENZ by 15.6 percentage points over the past year.
About LENZ Therapeutics
LENZ stock →LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees
About Zura Bio
ZURA stock →Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees
LENZ vs ZURA FAQ
Which is bigger, LENZ Therapeutics or Zura Bio?
LENZ Therapeutics (LENZ) is larger, with a market capitalization of $93.16M compared with $89.63M for Zura Bio (ZURA).
Which stock has performed better over the past year, LENZ or ZURA?
ZURA returned -74.37% over the past 12 months, compared with -89.97% for LENZ (price return, excluding dividends). Past performance does not predict future results.
Are LENZ Therapeutics and Zura Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.